The recent demonstration of genetic defects underlying obesity in inbred mice has raised hopes of treating obesity pharmacologically. The obese (ob) gene, its product leptin and the leptin receptor are involved in the regulation of both appetite and energy expenditure in the mouse. Mutations in the ob gene that lead to overeating and decreased physical activity have been demonstrated in morbidly obese mice, and treatment with recombinant leptin has resulted in a marked weight reduction in these animals and in normal mice. The pathophysiological role of leptin and its feedback system in man is as yet only partly known. This article focuses on recent data on the ob gene pathway and its potential role in man.
Introduction
It has long been established that obesity, defined as at least 20% over ideal weight, is accompanied by complications such as hypertension, non-insulindependent diabetes mellitus and atherosclerosis, which in turn cause ischaemic heart disease, stroke and premature death.
1 " 3 However, the mechanisms behind the imbalance in energy intake and energy expenditure that leads to obesity remain controversial. Obesity is often considered a mere 'lifestyle disease' caused by overeating and/or decreased physical activity. Even if these factors have a great influence on weight gain, recent research strongly indicates that hereditary factors could be equally or more important in the development of obesity and its complications.
The relative importance of genetic factors in obesity is under debate. 4 The first strong evidence came from family studies. In several studies, monozygotic twins, whether reared apart or together, had similar body weight development. 4 Furthermore, energy expenditure correlates in monozygotic twins. 4 From these and other studies, body mass index heritability has been estimated as about 40%. 5 During the last decade, much interest has focused on identifying genes that contribute to obesity and their mode of action. 4 Whole genome searches using polymorphic markers in rare human phenotypes that result in extreme obesity, and studies of human genes which are homologous to the mouse genes whose mutations can lead to obesity, have been two of the more common methods. Satiety has been suggested to be one of the most important factors in this energy balance. It is postulated that secondary to overeating, the storage of additional fat gives signals to the brain that the body is obese, which in turn makes the subject eat less and burn more fuel. 6 ' 7 Genes with potential to be involved in such processes have therefore been the focus of intense research. The ob gene has, in this respect, probably been the foremost candidate as a determinant of energy balance and weight maintenance.
Ob/ob and db/db mice-animal models for obesity research
In 1950, a genetic defect that results in profound obesity and type II diabetes was identified in inbred obese mice. 8 These obese mice eat continuously and weigh three times as much as normal mice. Furthermore, parabiosis experiments in which obese mutant homozygote ob/ob mice and normal wildtype mice were cross-connected circulatorily, resulted in decreased food intake and weight loss in the obese mice. These findings suggested that ob mice were lacking a blood-borne factor that regulated nutrient intake and metabolism. 9 Later it was confirmed that the obesity and type II diabetes in inbred ob mice were due to mutations in the ob gene.
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In November 1994, Jeffrey Friedman and collaborators used positional cloning to identify and sequence both the mouse obese {ob) gene and its human homologue.
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The ob gene was shown to be expressed solely in white and brown adipose tissue, and to encode a 167 amino acid sequence with characteristics of a secreted protein. , has no leptin mRNA expression, whereas the other (C57BL/6J) has a nonsense mutation resulting in a truncated, inactive form of leptin. This latter mutation results in a compensatory 20-fold increase in leptin mRNA. 11 Obesity in the mutant ob/ob mice can thus be attributed to deficiency in active leptin, which has consequently been identified as the postulated blood-borne hormone responsible for weight maintenance. In another type of obese, diabetic mice, a defect at the diabetes (db) locus has been demonstrated. If a normal mouse is circulatorily linked to a db/db mouse, the normal mouse will lose appetite, and eventually starve to death, suggesting that homozygote db mice have a defective receptor response to the leptin satiety signal. This may in turn lead to a compensatory increase in ob gene expression and in plasma leptin levels.
Weight-reducing effects of leptin in mice
Leptin secreted from fat cells is presumed to function as part of a signalling pathway from adipose tissue to the brain, and as a lipostat mechanism through modulation of satiety signals. Recently published data show that the hypothalamus, with its central role in the regulation of hunger and satiety, is the most likely target for leptin. 13 It has been suggested that when fat cells increase in number and size, the ob gene starts to produce leptin, which is secreted into the circulation. When leptin reaches the brain via regions outside the blood-brain barrier, including parts of the hypothalamus, it results in decreased appetite and increased metabolic rate. If no leptin is produced, no satiety is produced, and the subject continues to eat. The ventromedial nucleus of the hypothalamus is thought to have a central role in the regulation of feeding behaviour, and may therefore be a particularly important target organ for this protein.
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A few months after the cloning of the ob gene, it was demonstrated that treatment with leptin induces dramatic weight reduction in mice.
14 " 16 After 4 days of daily injections with recombinant leptin, morbidly obese ob mice consumed 60% less food compared to untreated ob mice, and their physical activity increased. After 4 weeks on leptin, weight was reduced by 40%. 15 This was entirely due to reduction of fat mass by approximately 75%. Furthermore, metabolic control in these diabetic mice improved considerably during this period, with regard to both plasma insulin and plasma glucose levels, which decreased. Normal mice treated with leptin lost almost all of their fat and decreased their initial body weight by 12% after 4 weeks treatment. 15 No obvious side-effects of leptin were seen. Leptin causes not only decreased food intake, but also increased energy expenditure in treated ob mice. When both leptintreated, and untreated ob mice were given equal amounts of a low-calorie diet, the leptin-treated mice lost more weight, strongly supporting a role for leptin in controlling energy expenditure. 14 Overall, these reports demonstrate that leptin secreted from fat cells is involved in the regulation of body weight. This has been further supported by the finding of a causal relationship between food intake, insulin levels and ob gene expression in rodents. 17 Ob gene expression exhibits diurnal variation and varies with changes in food intake. Fasting prevents the cyclic variation in leptin mRNA and decreases the expression of the gene, and leptin mRNA levels increase following food intake. 17 This latter finding is especially clear in mice fed with a high-fat diet, resulting in a sustained increase in circulating leptin in both normal and transgenic mice. 18 Furthermore, a single insulin injection in fasted rats increased leptin mRNA to levels of fed controls, regardless of its glucoselowering effects, 17 ' 19 while in adult obese rats, ob mRNA escapes downregulation, as normalization of hyperinsulinaemia due to fasting fails to reduce the high ob mRNA levels. 19 Glucocorticoids have also been shown to influence ob gene expression in rodents.
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Localization and role of the leptin receptor
As the brain controls metabolic rates and appetitefunctions that leptin affects-much interest has focused on searching for cerebral leptin receptors.
In December 1995, a year after the cloning of the ob gene, a research team from Millenium and Roche reported the finding of two related molecules that were presumed to mediate the effects of leptin in the body in mice and humans, respectively. 21 These molecules, predominantly found in the choroid plexus, both bound leptin and mapped to the same 6 cM interval on mouse chromosome 4 as cfb. 21 This study has been followed by two more important reports. The first shows that the leptin receptor (OB-R) has at least six alternatively spliced forms 22 and that one of these splice variants of the leptin receptor (Ob-Ra) is expressed in choroid plexus and may act to transport leptin to the cerebrospinal fluid.
Another variant (Ob-Rb) is expressed at a high level in the hypothalamus, and is abnormally spliced in C57BL/ks db/db mice. The mutant protein is missing the cytoplasmic region, and is likely to be defective in signal transduction. The second study demonstrates by genetic mapping and genomic analysis that mouse db, rat fatty (a homologue of db) and the gene encoding OB-R are all the same gene, and that phenotypes of mouse db and rat fatty are due to mutations in the ob (leptin) receptor. 23 These data support the hypothesis that the weight-reducing effects of leptin are mediated by signal transduction through a leptin receptor in the hypothalamus that modulates the activity of NPY, GLP-1 and other peptides that affect feeding behaviour. The Ob-Rb form of the receptor is also expressed at lower levels in brain, testes and adipose tissue. The hypothalamic mechanisms behind the weightreducing effects of leptin are so far only partly known. Recent data indicate that the two peptides cholecystokinin (CCK) and neuropeptide Y (NPY) both may have major roles in mediating leptin signals. 13 ' 24 CCK-B receptors have been demonstrated in the ventromedial nucleus of the hypothalamus and appear to be involved in central regulation of food intake, 24 while NPY mRNA levels are increased in the hypothalamic arcuate nucleus of ob mice. 13 Through radiolabelling of leptin, the binding sites for the hormone have recently been localized to this latter region. 13 Furthermore, both synthesis and release of hypothalamic NPY were decreased after leptin treatment. It is thus likely that the NPY neurons in the arcuate nucleus constitute an important target for circulating leptin. For example, it has recently been shown that in ob/ob mice systemic administration of leptin inhibits NPY gene overexpression in the arcuate nucleus and exerts a hypoglycaemic action that is partly independent of its weightreducing effects. 25 Both effects occur before reversal of the obesity syndrome. Defective leptin signaling due to either leptin deficiency (in ob/ob mice) or leptin resistance (in db/db mice) may therefore lead directly to hyperglycaemia and the overexpression of hypothalamic NPY, and contribute to explain the pathogenesis of obesity.
Studies of the ob gene in man
The role of the ob gene in man is yet only partly revealed. The human ob gene homologue is 84% identical to the mouse gene and is situated on chromosome 7. 11 Increased expression of leptin mRNA has been demonstrated in subcutaneous adipose tissue in massively obese subjects. 26 " 28 Expression was about 80% higher in obese subjects than in non-obese controls, in studies performed with both in situ hybridization histochemistry and reverse transcriptase PCR.
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' 27 From the present data it cannot, however, be determined whether the higher ob gene expression in the obese group is due to a higher transcription rate or to a slower mRNA turnover. Ob gene expression was 75% higher in obese women than in obese men, 26 suggesting an influence of sex hormones in ob gene regulation. Recent data using quantitative immunoprecipitation have shown that plasma leptin levels are markedly increased in obese subjects. 29 29 However, in spite of a strong correlation between plasma leptin concentration and BMI, there was a large heterogeneity in the leptin concentration among individuals at each BMI. In subjects with BMI > 4 0 there was a threefold difference in leptin mRNA and a 12-fold difference in the plasma leptin level between subjects. 26 ' 29 This indicates that leptin levels do not just reflect adipose tissue volume, and it remains possible that in man the secretion rate of leptin from the adipose tissue and/or the sensitivity to leptin at its site of action may be of major importance for the development of both obesity and its related metabolic complications. Presently available human data are compatible with feedback stimulation of the gene due to an impaired effect of leptin on the postulated hypothalamic satiety receptor. The upregulation of the ob gene in a large group of obese subjects has suggested the possibility of important mutations in this gene or in the gene coding for its corresponding receptor. However, large screenings of different patient categories are presently ongoing at our and other laboratories, and thus far no mutations in the human ob gene have been reported. Rare mutations in the human ob gene cannot explain the frequently observed elevation of leptin mRNA and plasma leptin in obese subjects. Furthermore, leptin levels are increased in non-genetic forms of obesity in rodents. 29 An alternative, and more likely, explanation is that the increased leptin mRNA levels in man are secondary to a decreased sensitivity in the hypothalamic satiety receptor itself, by analogy with the diabetes {db) mutant mouse, which has recently been shown to have a defective leptin receptor. 22 ' 23 However, it is also possible that a defect is present in a molecule involved in the ligand-receptor effector and feedback regulation. It should also be emphasized that the leptin feedback loop will not be the only pathway involved in human obesity. In a recent study on rodents, for example, leptin levels were increased in other obese mutants, including db, fat, tub, A Y mice and fa rats. 29 In these last, the leptin levels were increased 50-fold. Leptin activation may thus occur via multiple pathways in man as well.
The ob gene pathway-a source of future anti-obesity drugs?
Both the mouse and human forms of leptin have been used successfully for weight reduction in ob mice, especially in ob gene mutants. 14 " 16 However, no mutations have been found in the human ob gene. 27 In mice without ob gene mutations, very high doses of leptin were needed to reduce weight. 15 These observations, and the fact that plasma leptin varies with BMI, might suggest that this protein was simply a marker of adipose tissue mass. However, the great variability in plasma leptin between subjects in the same BMI range clearly indicates a pathophysiological role of the ob gene feedback loop. It is as yet unclear whether patients with high plasma leptin levels are clinically different from patients with low plasma concentrations, or whether these groups would respond differently to recombinant leptin. Present data are consistent with the possibility that, in some cases, subjects with decreased leptin recep- tor sensitivity in the hypothalamic satiety centre will develop obesity and a compensatory increase in plasma leptin levels. Hormonal upregulation is a frequent phenomenon in several clinical disorders, such as insulin resistance, and could be due to either complete insensitivity or decreased sensitivity to the hormone. Most probably the resistance to leptin is partial. If so, weight reduction could, at least theoretically, be achieved by administration of recombinant leptin. However, such treatment would be very expensive, as the doses required for weight loss would probably be very high, to judge from the data for wild-type mice. 15 Another factor that would limit the use of leptin in obesity is that the protein has to be injected. Oral leptin would be broken down in the gastrointestinal tract. In spite of these obstacles, lengthy toxicity and efficiacy studies are presently ongoing, to test the effects of leptin on man. For treatment of larger patient groups it is, however, necessary to develop alternative pharmacological strategies. As the major problem in human obese subjects appears to be a defective response to leptin, the recent discovery and characterization of the leptin receptor 21 undoubtedly widened our understanding of obesity and the underlying molecular and physiological mechanisms that regulate food intake and body weight, and may lead to new treatment strategies for obesity. However, it is important to stress that the ob gene is just one of several interesting genes involved in the regulation of satiety and energy expenditure. If eventually we develop an effective anti-obesity drug, other important problems will also arise. As obesity is present in about 25-30% of the population of the Western world, the costs of treating all affected individuals would be enormous. It will therefore be necessary to decide which patients should be treated. As obesity is a chronic disease, such treatment will probably have to be lifelong. Furthermore, safety and ethical regulations for weight-reducing substances has to be discussed, especially as leptin and leptin analogues, in case of potent fat-reducing effects, will have the potential to be abused among, for example, athletes, body builders and fashion models.
